Martien Kas, PRISM Coordinator: “Great to see the very enthusiastic PRISM team at the start-up meeting of the clinical deep phenotyping study in Amsterdam! We plan to have the first patient in the study towards the end of May 2017.”
Martien Kas, PRISM Coordinator: “Great to see the very enthusiastic PRISM team at the start-up meeting of the clinical deep phenotyping study in Amsterdam! We plan to have the first patient in the study towards the end of May 2017.”
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115916. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. This website reflects only the authors' view and the European Commission is not responsible for any use that may be made of the information it contains.